MedTrace Logo

Long-term Safety Follow-up in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products

NCT05010174 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2024-06-07

No results posted yet for this study

Summary

At the completion of primary follow-up of various Medeor Transplant studies (called parent studies), subjects receiving Medeor's cellular immunotherapy products will be followed annually for up to an additional 84 months (7 years), in order to evaluate for long-term safety.

Conditions

  • Immune Tolerance

Interventions

DRUG

MDR product

Observation of patients previously receiving MDR product(s)

Sponsors & Collaborators

  • Medeor Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Lenuta Micsa, MD · Medeor Therapeutics

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-11
Primary Completion
2024-04-30
Completion
2024-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05010174 on ClinicalTrials.gov